Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein

Custom-made monoclonal anti-idiotype antibodies (anti-Id MoAbs) have been tested as a treatment modality in 34 non-Hodgkin's lymphoma (NHL) patients. Partial or complete tumor remissions have been induced with this treatment in 68% of these patients. One mechanism by which anti-idiotype antibod...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 1994-02, Vol.83 (4), p.899-906
Hauptverfasser:	Vuist, W M, Levy, R, Maloney, D G
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal - therapeutic use Gene Expression Humans Immunoglobulin kappa-Chains - biosynthesis Immunoglobulin Light Chains - biosynthesis Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - metabolism Lymphoma, Non-Hodgkin - therapy Phosphotyrosine Protein-Tyrosine Kinases - biosynthesis Proto-Oncogene Proteins - biosynthesis Proto-Oncogene Proteins c-bcl-2 Receptors, Immunologic - physiology Signal Transduction - immunology Tumor Cells, Cultured Tyrosine - analogs & derivatives Tyrosine - analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!